Related Experiment Videos
Infliximab in chronic ocular inflammation
R P Baughman1, D A Bradley, E E Lower
1Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267-0565, USA. bob.baughman@uc.edu
International Journal of Clinical Pharmacology and Therapeutics
|February 12, 2005
Summary
Infliximab effectively treats chronic inflammatory eye disease, particularly when linked to sarcoidosis. This biologic therapy offers significant improvement for patients unresponsive to other treatments.
Area of Science:
- Ophthalmology
- Immunology
- Rheumatology
Background:
- Chronic inflammatory eye conditions pose significant challenges to vision and quality of life.
- Tumor necrosis factor (TNF) plays a key role in various chronic inflammatory diseases.
- Infliximab, a chimeric antibody targeting TNF, has shown efficacy in systemic inflammatory conditions.
Purpose of the Study:
- To evaluate the effectiveness of infliximab in managing chronic ocular inflammation.
- To assess infliximab's role in patients with treatment-resistant inflammatory eye diseases.
Main Methods:
- Retrospective review of 14 patients with chronic inflammatory ocular conditions treated over a two-year period.
- Patients received infliximab for various underlying conditions including sarcoidosis, Crohn's disease, and Behçet's disease.
- Analysis of treatment response in patients previously treated with etanercept.
Main Results:
- 14 patients with diverse ocular inflammatory conditions were treated with infliximab.
- Marked improvement in ocular inflammation was observed in all evaluable patients.
- Four patients who failed etanercept therapy responded well to infliximab.
Conclusions:
- Infliximab is a highly effective treatment for chronic inflammatory eye disease.
- The efficacy is particularly notable in cases associated with sarcoidosis.
- Infliximab represents a valuable therapeutic option for refractory ocular inflammation.